NRG GY005

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian

Status:

Open

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

NCT#02502266

Reactivated to accrual on Phase III with Amendment #7, 01/02/19.

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.